Literature DB >> 14969795

The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.

Ching-Chiang Yang1, Kang-Chu Chu, Wen-Meng Yeh.   

Abstract

Vascular epithelial growth factor (VEGF) regulates neovascualrization in malignant cells. VEGF as a mitogen is thought to alter cancer cell formation and tumor progression. We aimed to investigative the expression of the VEGF gene to evaluate their clinical significance in transitional cell carcinoma (TCC) of urinary bladder. Tissue samples from 161 patients with TCC were examined with an immunohistochemical stain for the expression of the VEGF gene. The expression rate was compared to 32 normal bladder mucosal samples obtained from transurehtral surgery from noncancer patients. The results revealed significant differences between normal urothelium (0%) and cancer tissue (54.7%) for the positive staining of VEGF protein (P < 0.001). With the progression of tumor grade and clinical staging, the positive rate of VEGF gene expression significantly increased. Expression of the VEGF gene in the invasive group was greater than that in the noninvasive group (P < 0.001). The results revealed that expression of the VEGF gene is proportional to the formation and progression of TCC. Therefore, abnormal expression of VEGF genes can be used as a prognostic marker in TCC of urinary bladder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14969795     DOI: 10.1016/S1078-1439(03)00015-2

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  23 in total

1.  Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.

Authors:  Przemyslaw Twardowski; Walter M Stadler; Paul Frankel; Primo N Lara; Christopher Ruel; Gurkamal Chatta; Elisabeth Heath; David I Quinn; David R Gandara
Journal:  Urology       Date:  2010-06-19       Impact factor: 2.649

Review 2.  Cancer models in Caenorhabditis elegans.

Authors:  Natalia V Kirienko; Kumaran Mani; David S Fay
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

Review 3.  Targeting angiogenesis in bladder cancer.

Authors:  Aymen A Elfiky; Jonathan E Rosenberg
Journal:  Curr Oncol Rep       Date:  2009-05       Impact factor: 5.075

Review 4.  The route to personalized medicine in bladder cancer: where do we stand?

Authors:  Francesco Massari; Chiara Ciccarese; Matteo Santoni; Matteo Brunelli; Alessandro Conti; Alessandra Modena; Rodolfo Montironi; Daniele Santini; Liang Cheng; Guido Martignoni; Stefano Cascinu; Giampaolo Tortora
Journal:  Target Oncol       Date:  2015-01-30       Impact factor: 4.493

5.  Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.

Authors:  Andrea B Apolo; Irina Ostrovnaya; Susan Halabi; Alexia Iasonos; George K Philips; Jonathan E Rosenberg; Jamie Riches; Eric J Small; Matthew I Milowsky; Dean F Bajorin
Journal:  J Natl Cancer Inst       Date:  2013-02-14       Impact factor: 13.506

6.  Bladder cancer: can we move beyond chemotherapy?

Authors:  Arlene Siefker-Radtke
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

7.  Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma.

Authors:  Shuzhe Yang; Xiaohou Wu; Chunli Luo; Cuicui Pan; Jun Pu
Journal:  World J Urol       Date:  2010-07-01       Impact factor: 4.226

8.  p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.

Authors:  Venkateshwar Madka; Yuting Zhang; Qian Li; Altaf Mohammed; Puneet Sindhwani; Stan Lightfoot; Xue-Re Wu; Levy Kopelovich; Chinthalapally V Rao
Journal:  Neoplasia       Date:  2013-08       Impact factor: 5.715

9.  Role of the androgen signaling axis in genitourinary malignancies.

Authors:  Brian M Shinder; Adam Shupe; Geun Taek Lee; Mark N Stein; Isaac Y Kim; Eric A Singer
Journal:  Transl Cancer Res       Date:  2018-08       Impact factor: 1.241

Review 10.  Optimal treatment for metastatic bladder cancer.

Authors:  Estrella M Carballido; Jonathan E Rosenberg
Journal:  Curr Oncol Rep       Date:  2014-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.